BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
27 juin 2023 07h00 HE
|
BioRestorative Therapies, Inc
No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of StudyDSMB Recommendation Allows for Open Enrollment MELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) --...
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
26 juin 2023 09h00 HE
|
Sermonix Pharmaceuticals Inc.
Sermonix used the Tempus TIME Trial® Network to enroll 45% of its ELAINE-2 patientsThe company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June ...
First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis
13 juin 2023 07h00 HE
|
First Wave BioPharma, Inc.
Two-thirds of patients have completed study, final patients being dosedTop line data read-out on track for July 2023 BOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc....
First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
11 mai 2023 07h00 HE
|
First Wave BioPharma, Inc.
Top line data read-out on track for July 2023 BOCA RATON, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a...
First Wave BioPharma to Participate in ‘Fireside Chat’ at the 35th Annual Roth Conference
28 févr. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
13 févr. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Global Progressive Supranuclear Palsy Clinical Trial Pipeline Highlights 2022
08 févr. 2023 13h23 HE
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Global Progressive Supranuclear Palsy Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.This...
Global Hemophilia-A Clinical Trial Pipeline Report 2022
02 févr. 2023 13h38 HE
|
Research and Markets
Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Hemophilia A Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.The report Hemophilia A...
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
02 févr. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
31 janv. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...